Blog
RSS FeedPosted by Michael Wonder on 10 Apr 2024
Making tender decisions: how does PHARMAC allocate its fixed budget?
10 April 2024 - The annual tender is one of several mechanisms PHARMAC uses to manage how much New Zealand ...
Posted by Michael Wonder on 16 Dec 2023
Has the Centers for Medicare Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?
15 December 2023 - The US Inflation Reduction Act of 2022 created several major policy changes to the pricing of prescription ...
Posted by Michael Wonder on 07 Dec 2023
Evolving our approach to COVID-19 vaccines and treatments
6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...
Posted by Michael Wonder on 06 Dec 2023
PHARMAC’s new equity policy
6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...
Posted by Michael Wonder on 21 Nov 2023
Funding verdict looms on ‘future of cancer therapy’
21 November 2023 - The chance of survival for hundreds of Australians living with a deadly type of blood cancer ...
Posted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 11 Oct 2023
PHARMAC needs to work for patients, not itself
10 October 2023 - “The internal chaos and siege mentality at PHARMAC is exactly why the next Government needs to ...
Posted by Michael Wonder on 12 Sep 2023
Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive Part B drugs
10 September 2023 - A retrospective analysis using a 20% nationally representative sample of 2015 to 2019 traditional Medicare Part B ...
Posted by Michael Wonder on 08 Sep 2023
Protecting Medicare’s discretion to say no to unproven therapies
8 September 2023 - Medicare, the largest health care payer in the nation, is also the single biggest source of revenue ...
Posted by Michael Wonder on 08 Sep 2023
Review of cancer related surrogate outcomes used for PBAC decision-making
8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...
Posted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...
Posted by Michael Wonder on 14 Aug 2023
In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need
14 August 2023 - Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her ...
Posted by Michael Wonder on 30 Jul 2023
PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist
29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...
Posted by Michael Wonder on 29 Jul 2023
Statutory authority for Medicare coverage decisions - CMS is an independent federal agency
28 July 2023 - It is time for the public to recognize and strongly support the authority of the US Centers ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...